BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 12409653)

  • 1. Proteasome inhibitors as new anticancer drugs.
    Adams J
    Curr Opin Oncol; 2002 Nov; 14(6):628-34. PubMed ID: 12409653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical update: proteasome inhibitors in solid tumors.
    Lenz HJ
    Cancer Treat Rev; 2003 May; 29 Suppl 1():41-8. PubMed ID: 12738242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition: a novel approach to cancer therapy.
    Adams J
    Trends Mol Med; 2002; 8(4 Suppl):S49-54. PubMed ID: 11927288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs.
    Giuliano M; D'Anneo A; De Blasio A; Vento R; Tesoriere G
    Ital J Biochem; 2003 Jun; 52(2):112-21. PubMed ID: 14677428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of the proteasome inhibitor Velcade (Bortezomib).
    Adams J; Kauffman M
    Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.
    Cusack JC
    Cancer Treat Rev; 2003 May; 29 Suppl 1():21-31. PubMed ID: 12738240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proteasome: structure, function, and role in the cell.
    Adams J
    Cancer Treat Rev; 2003 May; 29 Suppl 1():3-9. PubMed ID: 12738238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential for proteasome inhibition in the treatment of cancer.
    Adams J
    Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition in cancer: development of PS-341.
    Adams J
    Semin Oncol; 2001 Dec; 28(6):613-9. PubMed ID: 11740819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical update: proteasome inhibitors in hematologic malignancies.
    Richardson P
    Cancer Treat Rev; 2003 May; 29 Suppl 1():33-9. PubMed ID: 12738241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
    Shah SA; Potter MW; McDade TP; Ricciardi R; Perugini RA; Elliott PJ; Adams J; Callery MP
    J Cell Biochem; 2001 Apr 2-27; 82(1):110-22. PubMed ID: 11400168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.
    Ling YH; Liebes L; Ng B; Buckley M; Elliott PJ; Adams J; Jiang JD; Muggia FM; Perez-Soler R
    Mol Cancer Ther; 2002 Aug; 1(10):841-9. PubMed ID: 12492117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Proteasome inhibitor].
    Yamamura M; Hirai T; Yamaguchi Y
    Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathways that modify tumor radiation response.
    Pervan M; Pajonk F; Sun JR; Withers HR; McBride WH
    Am J Clin Oncol; 2001 Oct; 24(5):481-5. PubMed ID: 11586100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells].
    Satou Y; Matsuoka M
    Nihon Rinsho; 2004 Jul; 62(7):1363-7. PubMed ID: 15283157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
    Russo SM; Tepper JE; Baldwin AS; Liu R; Adams J; Elliott P; Cusack JC
    Int J Radiat Oncol Biol Phys; 2001 May; 50(1):183-93. PubMed ID: 11316563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the proteasome inhibitor bortezomib in multiple myeloma.
    Richardson PG
    Expert Opin Pharmacother; 2004 Jun; 5(6):1321-31. PubMed ID: 15163277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
    Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Fanourakis G; Gu X; Bailey C; Joseph M; Libermann TA; Treon SP; Munshi NC; Richardson PG; Hideshima T; Anderson KC
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14374-9. PubMed ID: 12391322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
    Cusack JC; Liu R; Houston M; Abendroth K; Elliott PJ; Adams J; Baldwin AS
    Cancer Res; 2001 May; 61(9):3535-40. PubMed ID: 11325813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
    Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.